Tel Aviv - Delayed Quote ILA

Purple Biotech Ltd (PPBT.TA)

Comparar
5.90
-0.30
(-4.84%)
Al cierre: January 30 at 5:24:48 PM GMT+2
Todos Todos Favoritos Texto Estadísticas Datos técnicos Fibonacci Marcas Líneas
Cargando gráfico de PPBT.TA

Noticias recientes: PPBT.TA

Más detalles
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire last month
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire last month
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
GlobeNewswire last month
Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Reports Third Quarter 2024 Financial Results
GlobeNewswire 2 months ago
Purple Biotech Unveils Promising Biomarker for Cancer Therapy

Purple Biotech Unveils Promising Biomarker for Cancer Therapy
TipRanks 2 months ago
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
GlobeNewswire 2 months ago
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire 3 months ago
Purple Biotech Unveils CAPTN-3 Cancer Therapy

Purple Biotech Unveils CAPTN-3 Cancer Therapy
TipRanks 3 months ago
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire 3 months ago
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
GlobeNewswire 4 months ago
Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested

Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested
TipRanks 4 months ago
Más detalles

Pizarras relacionadas

ORMP.TA Oramed Pharmaceuticals Inc.
796.60
-0.75%
 
ENLV.TA Enlivex Therapeutics Ltd.
396.00
-0.63%
 
LCTX.TA Lineage Cell Therapeutics, Inc.
223.00
-5.55%
 
EVGN.TA Evogene Ltd.
551.10
-3.49%
 
BLRX.TA BioLineRx Ltd.
2.4000
-25.00%
 
ORMP Oramed Pharmaceuticals Inc.
2.2000
-2.22%
 
ENLV Enlivex Therapeutics Ltd.
1.1100
+2.78%
 
ANRO Alto Neuroscience, Inc.
4.4600
+5.44%
 
RLMD Relmada Therapeutics, Inc.
0.3540
-2.88%
 
APTO Aptose Biosciences Inc.
0.1691
-2.08%